![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Solvay Pharmaceuticals |
---|---|
Information provided by: | Solvay Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00703482 |
The purpose of this study was to study the effect of different combinations of fenofibrate and coenzyme Q10 on ventricular diastolic function in patients with Type II diabetes
Condition | Intervention | Phase |
---|---|---|
Patients With Type 2 Diabetes |
Drug: Fenofibrate/CoQ10 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes |
Enrollment: | 278 |
Study Start Date: | May 2003 |
Study Completion Date: | September 2004 |
Primary Completion Date: | September 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Drug: Fenofibrate/CoQ10
Fenofibrate pbo/CoQ10 placebo
Drug: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 placebo
|
2: Active Comparator |
Drug: Fenofibrate/CoQ10
Fenofibrate pbo/CoQ10 200 mg
|
3: Active Comparator |
Drug: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 placebo
|
4: Experimental |
Drug: Fenofibrate/CoQ10
Fenofibrate 80/CoQ10 100 mg
|
5: Experimental |
Drug: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 100 mg
|
6: Experimental |
Drug: Fenofibrate/CoQ10
Fenofibrate 80 /CoQ10 200 mg
|
7: Experimental |
Drug: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 200 mg
|
Ages Eligible for Study: | 40 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients with one of the following pathology:
Australia | |
Site 001 | |
Perth, Australia | |
Site 002 | |
Fremantle, Australia | |
Site 003 | |
Nedlands, Australia |
Study Director: | Global Clinical Director Solvay | Solvay Pharmaceuticals |
Responsible Party: | Solvay Pharmaceuticals ( Jean Claude Ansquer ) |
Study ID Numbers: | CFEN0205 |
Study First Received: | June 20, 2008 |
Last Updated: | June 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00703482 |
Health Authority: | Australia: National Health and Medical Research Council |
Ventricular diastolic Function Diabetes |
Metabolic Diseases Ubiquinone Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Procetofen Coenzyme Q10 |
Antimetabolites Molecular Mechanisms of Pharmacological Action Vitamins Growth Substances Therapeutic Uses |
Antilipemic Agents Physiological Effects of Drugs Micronutrients Pharmacologic Actions |